Novel Therapies to Address Unmet Needs in ITP

Novel Therapies to Address Unmet Needs in ITP

Primary immune thrombocytopenia (ITP) is an autoimmune disorder that causes low platelet counts and subsequent bleeding risk. Although current corticosteroid-based ITP therapies are able to improve platelet counts, up to 70% of subjects with an ITP diagnosis do not achieve a sustained clinical respo...

Full description

Bibliographic Details
Main Authors: María Eva Mingot-Castellano, José María Bastida, Gonzalo Caballero-Navarro, Laura Entrena Ureña, Tomás José González-López, José Ramón González-Porras, Nora Butta, Mariana Canaro, Reyes Jiménez-Bárcenas, María del Carmen Gómez del Castillo Solano, Blanca Sánchez-González, Cristina Pascual-Izquierdo, on behalf of the GEPTI
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Pharmaceuticals
Subjects:
immune thrombocytopenia
thrombopoietin
autoantibodies
platelets
targeted therapies
Online Access:https://www.mdpi.com/1424-8247/15/7/779

Internet

https://www.mdpi.com/1424-8247/15/7/779

Similar Items